```html

Graft‑versus‑Host Disease Skin Changes

What is Graft‑versus‑Host Disease Skin Changes?

Graft‑versus‑Host Disease (GVHD) is an immune‑mediated complication that can occur after an allogeneic hematopoietic stem cell transplant (HSCT) or, less commonly, after a solid‑organ transplant that includes donor immune cells. In GVHD, donor T‑lymphocytes recognize the recipient’s tissues as foreign and launch an attack. The skin is the most frequently involved organ, with up to 80 % of patients experiencing cutaneous manifestations at some point after transplant.<sup>1</sup>

Skin changes in GVHD range from a mild, sun‑burn‑like rash to severe, painful ulcerations and sclerotic plaques that can limit mobility. The severity is classified as acute (typically within the first 100 days post‑transplant) or chronic (after 100 days). Both forms can coexist, and early identification is crucial because skin findings often precede involvement of the liver, gastrointestinal (GI) tract, or lungs.

Common Causes

While GVHD itself is the primary cause of these skin changes, several factors increase the risk or trigger the appearance of the rash:

• Allogeneic stem‑cell transplantation – especially from a mismatched donor.
• Peripheral blood stem cell grafts – contain more mature T‑cells than bone‑marrow grafts.
• Reduced‑intensity conditioning regimens – can alter immune reconstitution.
• Older recipient age – associated with a higher incidence of chronic GVHD.
• Donor–recipient gender mismatch (female donor to male recipient).
• Previous episodes of acute GVHD – increase risk of chronic skin disease.
• Infections or drug reactions – can mimic or exacerbate GVHD rash.
• Radiation therapy to the skin – may potentiate inflammatory skin responses.
• Underlying autoimmune disorders – predispose to immune dysregulation after transplant.
• Use of certain immunosuppressive drugs (e.g., calcineurin inhibitors) – under‑ or over‑suppression can tilt the balance toward GVHD.

Associated Symptoms

Skin involvement rarely occurs in isolation. The following symptoms often appear alongside the rash and can help differentiate GVHD from other dermatologic conditions:

• Pruritus (itching): especially intense in acute GVHD.
• Burning or tenderness: may be present in both acute and chronic forms.
• Fever and malaise: systemic signs common in acute GVHD.
• Gastrointestinal disturbances: diarrhea, abdominal pain, or nausea, indicating gut GVHD.
• Liver enzyme elevation: jaundice or right‑upper‑quadrant discomfort signals hepatic involvement.
• Mouth and genital ulcers: mucosal GVHD often accompanies cutaneous disease.
• Dry eyes or sclerotic changes: more typical of chronic GVHD.
• Weight loss or decreased appetite: especially in chronic disease.

When to See a Doctor

Because GVHD can progress rapidly and affect multiple organs, timely medical evaluation is essential. Seek professional care if you notice any of the following:

• New rash that appears within weeks after transplant, especially if it is widespread or worsening.
• Skin that becomes painful, blistered, or ulcerated.
• Significant itching that interferes with sleep or daily activities.
• Redness that spreads beyond the initial area or forms raised plaques.
• Associated GI symptoms (persistent diarrhea, vomiting) or liver signs (yellowing of skin/eyes).
• Fever >38 °C (100.4 °F) without an obvious infection.
• Rapid swelling or tightening of skin on the hands, arms, or trunk that limits movement.

Early dermatology or transplant‑team consultation can prevent progression to severe disease.

Diagnosis

Diagnosing GVHD skin changes involves a combination of clinical assessment, laboratory testing, and sometimes skin biopsy.

Clinical Evaluation

• History: timing relative to transplant, donor‑recipient match, prior GVHD episodes, current immunosuppression.
• Physical exam: distribution, morphology (maculopapular rash, lichenoid plaques, sclerodermatous changes), and extent measured as a percentage of body surface area (BSA).

Laboratory & Imaging

• Complete blood count (CBC) and liver function tests to assess systemic involvement.
• Serum cytokine levels (e.g., IL‑2R) may support severity grading.
• Imaging (ultrasound or CT) if organ involvement beyond skin is suspected.

Skin Biopsy

A 4‑mm punch biopsy is the gold standard when the diagnosis is uncertain or to differentiate GVHD from drug eruptions, infection, or autoimmune skin disease. Characteristic histopathologic features include:

• Interface dermatitis with basal vacuolization.
• Apoptotic keratinocytes (satellitosis).
• Dermal inflammatory infiltrate rich in lymphocytes and macrophages.
• In chronic disease, dermal fibrosis and sclerosis.

Grading Systems

Clinicians often use the Mount Sinai Acute GVHD International Consortium (MAGIC)* criteria for acute disease and the NIH Consensus criteria for chronic GVHD. These systems consider skin BSA involvement, rash severity, and impact on function.

Treatment Options

Management aims to control the immune response, relieve symptoms, and preserve skin integrity.

Medical Therapies

• Systemic corticosteroids (e.g., prednisone 1–2 mg/kg/day) are first‑line for acute skin GVHD. Tapering is guided by response.
• Topical steroids (high‑potency clobetasol 0.05 % ointment) for limited‑area rash or as adjunct to systemic therapy.
• Calcineurin inhibitors (tacrolimus or cyclosporine) – often combined with steroids for synergistic immunosuppression.
• Mycophenolate mofetil (MMF) – added when steroids are insufficient or as steroid‑sparing agent.
• Ruxolitinib (JAK1/2 inhibitor) – FDA‑approved for steroid‑refractory acute GVHD; effective for skin and gut manifestations.
• Extracorporeal photopheresis (ECP) – especially useful in chronic GVHD with sclerotic skin changes.
• IL‑2 receptor antagonists (basiliximab, daclizumab) – considered in selected cases.
• Antifibrotic agents such as imatinib for severe sclerodermatous disease.

Supportive & Home Care

• Moisturizers: thick, fragrance‑free emollients (e.g., petrolatum, ceramide‑containing creams) applied 2–3 times daily to maintain barrier function.
• Gentle skin cleansing: use lukewarm water and non‑soap cleansers; avoid scrubbing.
• Sun protection: broad‑spectrum SPF 30+ sunscreen, protective clothing; UV exposure can exacerbate rash.
• Antihistamines: diphenhydramine or cetirizine for itching.
• Pain management: acetaminophen or low‑dose opioids as prescribed; topical lidocaine patches for localized pain.
• Wound care: sterile dressings for erosions, use of non‑adhesive silicone pads to prevent trauma.
• Hydration & nutrition: adequate fluid intake; protein‑rich diet supports skin healing.
• Physical therapy: gentle range‑of‑motion exercises prevent contractures from sclerotic plaques.

Prevention Tips

While GVHD cannot be completely avoided, several strategies reduce the risk or lessen the severity of skin involvement:

• Optimal donor matching: high‑resolution HLA typing decreases allo‑reactivity.
• Use of reduced‑dose T‑cell grafts: ex‑vivo T‑cell depletion in high‑risk patients.
• Prophylactic immunosuppression: standard regimens include a calcineurin inhibitor plus methotrexate or mycophenolate.
• Early tapering of steroids only after stable skin response: abrupt reduction can trigger flare.
• Regular skin assessments: transplant centers usually schedule weekly dermatologic exams for the first 3 months.
• Prompt treatment of infections: viral (e.g., HHV‑6, CMV) and bacterial skin infections can aggravate GVHD.
• Avoidance of irritants: harsh soaps, alcohol‑based hand sanitizers, and tight clothing.
• Vaccination and prophylactic antivirals: reduce viral reactivations that may mimic or trigger GVHD.

Emergency Warning Signs

Key Take‑aways

• Skin changes are the most common manifestation of GVHD and can signal both acute and chronic disease.
• Early recognition, appropriate grading, and prompt initiation of systemic therapy dramatically improve outcomes.
• Supportive skin care, infection prevention, and regular follow‑up are essential components of long‑term management.
• Severe or rapidly progressing symptoms constitute an emergency; do not delay medical evaluation.

---

Sources:

1. Mayo Clinic. Graft‑versus‑host disease (GVHD). 2023.
2. National Institutes of Health. NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD. 2022.
3. Cleveland Clinic. Acute GVHD: Diagnosis and Management. 2024.
4. American Society of Clinical Oncology. Guidelines for the Management of Acute GVHD. 2022.
5. World Health Organization. Allogeneic Hematopoietic Stem Cell Transplantation: Recommendations. 2021.

```